The Advocate: Supporting the Patient Voice is excited to announce the results of its 2025 U.S. focused Patient Advocacy report. The report provides an in-depth look at feedback from Patient Advocacy Organizations & Professional Societies/Associations and their relationship with the pharmaceutical community. This information will help stakeholders understand new & innovative ways they can best work with Patient Advocacy Organizations & Professional Societies/Associations to improve healthcare for all patients. The Advocate would like to thank their many sponsors in the pharmaceutical community for making this report possible & for the respondents who gave their time & feedback!

•    For the seventh consecutive year, Johnson & Johnson Innovative Medicine ranked #1 for patient advocacy.  Johnson & Johnson Innovative Medicine is noted for “actively exploring how to expand their support while other companies are pulling back," along with “developing trials to support the lived experience for people on their treatment” and “investing in relationships with organizations like ours and treating our relationship like it is paramount to their success."

•    Merck and AstraZeneca showed improvement and moved up in three out of five benchmarking categories. 
     o    Patient advocates noted Merck is “extremely patient centric and includes              the patient community in conversations and panels."
     o    Patient advocates noted AstraZeneca’s  “clear and consistent two-way                    communication, innovative thinking and approaches to patient education."

•    Since 2019 Pfizer has remained consistent, placing 2nd in Patient/Professional Group Relations.  Pfizer is noted for “investing in many ad boards to find the right way to partner with organizations and physicians to best divulge their treatment options for best patient care."

•    ViiV demonstrated the strongest year over improvement for two of the five benchmarking categories – Advancing Patient Treatment and Patient/Professional Group Relations.  Patient advocates noted “advancing new, easier to tolerate drug regimens and patient access” and “ongoing and meaningful collaboration with stakeholders."

•    Other organizations of note include: Amgen and Novartis showed significant improvement in the areas of Programmatic Support and Bristol-Myers Squibb showed improvement in the Corporate Reputation benchmarking category and moved up from 3rd place in 2024 to 1st place in 2025.  

The Advocate: Supporting the Patient Voice's goal is to understand the relationship between advocates & the pharmaceutical industry. It's their mission to ensure that patients remain at the center of all healthcare decisions - may it be in their doctor's office, within the walls of the Payer of PBM or up on Capitol Hill. We understand that the pharmaceutical community aligns with their mission in their goals to ensure patients get access to the products they & their physicians have decided. It seeks to serve as a beacon for the pharmaceutical community to always find their way back to the patient by elevating the voice of their loudest supporters – the advocacy organizations. The Advocate does this through a syndicated market research offering for the pharmaceutical community to gain insights into the needs of the patients they serve & the patient advocate organizations they fight side by side with on numerous issues.

The research and expertise of The Advocate allows them to guide today's pharmaceutical advocacy teams, aid in the development & implementation of patient centricity programs within pharmaceutical companies & consult on the use of the patient voice throughout the products lifecycle. Reach out to Ryan & his team directly with any questions about the current report, or any previous or future reports at [email protected] or www.thebrooksgrouponline.com.